1. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers
   Tsutomu Nishida et al, 2019, Hepatology International CrossRef
2. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review
   Rhiannon M. Bath et al, 2019, Annals of Pharmacotherapy CrossRef
3. Hepatitis B Core Antibody: Role in Clinical Practice in 2020
   Robert G. Gish et al, 2020, Current Hepatology Reports CrossRef
4. Risk factors for de novo hepatitis B during solid cancer treatment
   Rie Sugimoto et al, 2020, World Journal of Clinical Cases CrossRef
5. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation
   Maki Ohkubo et al, 2024, Biological and Pharmaceutical Bulletin CrossRef
6. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
   Joyce Wing Yan Mak et al, 2023, World Journal of Gastroenterology CrossRef
7. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
   Yu-Fen Tsai et al, 2019, PeerJ CrossRef
8. Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection
   Chih-Lin Lin et al, 2021, Hepatitis B Virus and Liver Disease CrossRef